Masami Otsuka
Co-founder & R & D Director, Science Farm Ltd. (Professor), Ph.D.
Department of Drug Discovery, Science Farm Ltd., 862-0976, Kumamoto, Japan
Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 862-0973, Kumamoto, Japan

Masami Otsuka started his research career in a field of medicinal chemistry at University of Tokyo in 1977 and obtained his PhD in 1983 and further worked in the same university in the field of chemical-biological study of anticancer drugs. He moved to Kyoto University in 1992 and worked in signal transduction field. In 1997 he was promoted as a Professor of Kumamoto University, School of Pharmacy and worked on bioorganic medicinal chemistry until his retirement in 2019. Currently he is a Director of R & D. Science Farm Ltd., a startup company established in 2018. He has many collaborative studies with different research groups from Turkey.

Mikako Fujita
(Professor), Ph.D.
Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 862-0973, Kumamoto, Japan

Mikako Fujita started her research career in a field of organic chemistry at University of Tsukuba in 1985, and later she moved on to medicinal chemistry, with obtaining her PhD at Kyoto University in 1996. She also worked in virology field at Tokushima University from 1999 to 2006. At the moment, her laboratory in Kumamoto University is aiming at drug discovery and functional elucidation of viral proteins. Recently, she has many collaborative studies with different research groups from Turkey.

Halilibrahim Ciftci
Co-founder & Vice President, Science Farm Ltd. (Associate Professor), Ph.D.
Department of Drug Discovery, Science Farm Ltd., 862-0976, Kumamoto, Japan
Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 862-0973, Kumamoto, Japan
Department of Molecular Biology and Genetics, Koc University, 34450 Istanbul, Turkey

Halilibrahim Ciftci received his BSc. in Chemistry from Ege University, Turkey in 2006 and M.Sc. in Cancer Pharmacology from Institute of Cancer Therapeutics, University of Bradford, UK in 2008. Then, he worked at major Turkish pharmaceutical companies (i.e. Neutec, Bilim and Deva) as an R&D senior scientist to manage all technical aspects of the product development processes. After working for 4 years at major pharmaceutical companies, he chose to return to his academic career at the School of Pharmacy in Kumamoto University, Japan in 2012 as a Japanese Government (MEXT) PhD scholar to develop anticancer and anti-HIV drug candidates. He received his Ph.D. in Pharmaceutical Sciences in 2016 and immediately after, he began working as a JSPS (Japanese Society for the Promotion of Science) Postdoctoral Fellowship at the same school. During his postdoc, he had a close collaboration with Stanford PULSE Institute for SFX-based drug development. In 2017, they (together with professor Masami Otsuka) entered the TECH PLANTER start-up business project competition with a project named as “Finding a Cure for HIV and AIDS by the New Treatment” and received two awards (Special Award, and Hakuzo Medical Award) in Japan. Subsequently, he launched a start-up company in 2018 named Science Farm Ltd. together with professor Masami Otsuka and Mr. Kataoka Yoshitomo to commercialize their patented drugs through pharmaceutical companies. In 2019, their company opened a new department at the School of Pharmacy in Kumamoto University called “Medicinal and Biological Chemistry Science Farm Joint Research Laboratory”. He is currently working as Vice President of this company to make Japanese drugs accessible in Turkey and also leading anti-HIV, anticancer and anti-ALS drug development studies at Koc University KUYBIIG-M as a Visiting Researcher.

(Assist. Prof), Ph.D.

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul Medipol University

Hacer Karatas Brıstow received her PhD in Medicinal Chemistry at the University of Michigan, where she focused on structure-based development of peptidomimetic inhibitors of the MLL1-WDR5 protein-protein interaction, an epigenetic target for leukemia therapy. After graduation, she joined a bio-imaging laboratory at EPFL (Switzerland) to develop bioluminescent assay technologies for monitoring cellular uptake of peptides and antibodies. Later, she joined the Department of Chemical Biology at the Max Planck Institute of Molecular Physiology (Germany) for her post-doctoral studies on identifying covalent inhibitors of TEAD transcriptional factor. She recently started as assistant professor at the Department of Pharmaceutical Chemistry in Istanbul Medipol University where she is working on protein-protein interaction inhibitors of Hox-Pbx transcription factors.  



Mohammad A. OBEID

(Assoc. Prof.), Ph.D.


Associate professor of nanomedicine and drug delivery, Department of pharmaceutics and pharmaceutical technology, Faculty of Pharmacy, Head of Technology and Transfer Office (TTO), International relations and projects department, Yarmouk University, Irbid-Jordan

Dr. Mohammad Obeid has experience of teaching in Higher Education, conducting research and securing funding. The Research Group is applying Nano/Microfabrication techniques in Pharmaceutical drug delivery applications and manufacturing. More specifically, our areas of interest include: Microfluidics (Particle Formulation & Chip Manufacturing), targeted drug delivery, nucleic acids delivery, In vitro and in vivo studies, Electrospinning (Melt & Solution).


(22) Mohammad Obeid | LinkedIn

قاعدة بيانات اعضاء هيئة التدريس (yu.edu.jo)


(Assist. Prof.), Ph.D.


Department of Pharmacy, Università degli Studi G. d’Annunzio Chieti e Pescara, Italy

Prof. Simone Carradori completed his PhD in “Pharmaceutical Sciences” at Sapienza University of Rome (Italy). Currently, he is an Associate Professor in Medicinal Chemistry at the Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara (Italy). Prof. Carradori has collaborated and still collaborates with several departments abroad. The scientific activity is mainly focused on the synthesis and characterization of heterocyclic derivatives and the extraction/modification of natural compounds. These contributions led to the discovery of new biologically active agents characterized by in vitro, in vivo, and in silico studies as well as the drug repositioning in cancer and antimicrobial therapy, as documented from about 210 papers in international peer-reviewed journals, one European patent, and participation in numerous conferences. Moreover, Prof. Carradori is a member of the Editorial Board of several peer-reviewed journals (Hirsch index 42, citations ~5776).





Department of Pharmacology, Faculty of Pharmacy, Ege University, Turkey

Dr. Yıldırım Buharalıoğlu graduated from Ege University, Faculty of Pharmacy in 2009 with first rank and completed her master’s degree in Pharmacology. Then, she was awarded by PhD Scholarship Abroad from The Council of Higher Education of Turkey and did her PhD   at University of Bristol, School of Clinical Sciences in the field of Molecular Pharmacology under supervision of a world-class scientist Prof Andrew Newby. Her PhD thesis is mainly focussed on the epigenetic regulation during human macrophage differentiation and polarization. To date she has presented her work in prestigious meetings at University of Cambridge, Harvard Medical School and was awarded British Atherosclerosis Society Young Investigator Prize. At the moment she is working on epigenetic regulation mechanisms in prostate cancer as an independent young scientist and aiming to carry on her academic career in the field of cancer epigenetics.


(Professor of Pharmacology)


Department of Pharmacology, Vanderbilt University Medical School, USA

Dr. Claus Schneider was born and raised in the Frankonia part of Bavaria, Germany. He attended the University of Wurzburg (Germany) and obtained a PhD in food chemistry in 1997. He then moved to Vanderbilt University (Nashville, TN, U.S.A.) for postdoctoral training with Prof. Alan Brash to work on mechanisms of enzymatic and non-enzymatic lipid oxidation He is now a Professor of Pharmacology at Vanderbilt University. Dr. Schneider’s research focuses on the identification and characterization of novel eicosanoid lipid mediators and on bioactive natural products. Dr. Schneider’s lab has identified the chemical mechanisms of degradation of curcumin, resulting in hypotheses on how the degradation products mediate biological effects of the parent compound. Dr. Schneider served as an Associate Editor for the journal Molecular Nutrition and Food Research from 2005 to 2016 and has been a member of the Executive Editorial Board since then. He has been on the editorial board of the Journal of Biological Chemistry since 2016 and became an Associate Editor of Free Radical Research in 2020.


Aykut ÜREN, M.D.

(Tenure Line-Professor)


Department of Oncology, Georgetown University Medical Center, Washington, DC, USA

Dr. Aykut Üren is a full professor at the Department of Oncology Georgetown University in Washington, DC. He has a secondary appointment with the Department of Biochemistry and Molecular & Cellular Biology. His research focuses on molecular mechanisms of malignant transformation and drug discovery in pediatric sarcomas. Some of the active projects in his laboratory include development of targeted therapies against EWS-FLI1 and CD99 in Ewing’s Sarcoma, ERG in prostate cancer, ezrin in osteosarcoma and Pax3-Foxo1 in rhabdomyosarcoma. He also runs a core facility at Georgetown University that provides surface plasmon resonance technology (Biacore 4000 and Biacore T200) to academic institutions and biopharmaceutical companies. He teaches tumor biology to graduate students and gross anatomy to medical students, for which he has received multiple teaching awards including the Golden Apple and Golden Orchard.


Yahya GÜZEL, Ph.D.



Department of Chemistry, Faculty of Science, Erciyes University, Kayseri, Turkey

Yahya Güzel started his research career in 1984 at Atatürk University in the field of Organic Chemistry. He received his Ph.D. from Erciyes University in 1990 and has been working in the field of computational chemistry at the same university since 1992. He was promoted to Professor in 2002. He has experience in teaching and conducting research in the field of Higher Education. He develops and applies his own software called MCET to determine the pharmacophore structure, which is important in drug design and QSAR studies.


Phillip BOWEN, Ph.D.

(Professor of Pharmaceutical Sciences)


Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, USA

Dr. Bowen’s research interests span the fields of organic, medicinal, and theoretical chemistry. Specifically, the Bowen research group is using computational chemistry and computer-assisted drug design (CADD) methods for the design of novel antiangiogenic agents for the treatment of cancer and related diseases.





Department of Pharmaceutical Chemistry

Faculty of Pharmacy, Gazi University, Turkey

Prof. Banoglu received his PhD in Medicinal and Natural Products Chemistry from the University of Iowa (USA) in 1997, and later joined to Gazi University at the Department of Pharmaceutical Chemistry where he still works as the Department Head. He also worked in Aberdeen University (Scotland) as a British Council Scholar, in Kumamoto University (Japan) as a JICA scholar, and did postdoctoral study in the Department of Biomedical Sciences at the University of Rhode Island (USA). Currently, his research group is involved in the discovery and development of new molecules for pathologies associated with cancer development and inflammation, especially targeting 5-lipoxygenase-activating protein (FLAP), and microsomal prostaglandin E2 synthase-1 (mPGES-1), which are important targets for treatment of chronic inflammatory and cardiovascular diseases and cancer. An important aspect of his research activities includes the combined use of chemical, computational and pharmacological tools in order to eventually provide new chemotypes for novel therapies of inflammation-related disorders and cancer. His second research area is the development of novel anti-cancer drug chemotypes, especially targeting PI3K/Akt signaling pathway. He is also the co-founder of the OncoCube Therapeutics (USA) where the preclinical to clinical studies are being continued for the small molecule cancer therapeutics. He is also the Principal Member of the Turkish Academy of Sciences (TÜBA).



Adil Mardinoglu, PhD

(Professor of Systems Biology)


Oral & Craniofacial Sciences, Faculty of Dentistry, King’s

College London, İngiltere

Prof. Dr. Adil Mardinoğlu received his bachelor’s degree from Istanbul Technical University, Faculty of Electrical and Electronics Engineering (2005) and his PhD in magnetic drug targeting applications from Waterford Institute of Technology (2009) in Ireland. He worked as a postdoctoral researcher at Trinity College Dublin in Ireland between 2009-2010 and Chalmers University of Technology in Sweden between 2010-2015. He continued his studies as an assistant professor in 2015 and an associate professor in 2018 at KTH-Royal Institute of Technology in Sweden. He held administrative positions at various levels at KTH-Royal Institute of Technology between 2016-2018. In 2018, he started working as a Professor at King’s College London in England. Prof. Dr. Adil Mardinoğlu conducted studies in the fields of computational biology, molecular biology and drug development at King’s College London and KTH-Royal Institute of Technology. The aim of the research group led by Prof. Mardinoğlu is to examine cellular network structures with bioinformatics-based computational methods and from a systems biology perspective, to make inferences about the working principles of the cell and disease mechanisms and to develop innovative drug and early diagnosis systems for chronic diseases such as diabetes, fatty liver disease, cancer, and neurodegenerative diseases. Prof. Dr. Mardinoğlu contributed to the international Human Cell Atlas program with atlas of human tissue, cell compartments and pathology within the Human Protein Atlas program in Sweden. He has published more than 170 research and review articles in international peer-reviewed journals such as Science, Cell Metabolism, Cell Reports, Cell Systems, Nature Communications, Nature Reviews Gastroenterology & Hepatology, PNAS, Molecular Systems Biology, Metabolic Engineering, Drug Discovery Today and EbioMedicine. It has received 20,000 citations in total, with an H index of 46 and an i10 index of 95. He has patents for the development of new drugs for fatty liver disease and different types of cancer.


Scroll to Top